SG11202009526RA - Methods of treating ulcerative colitis - Google Patents

Methods of treating ulcerative colitis

Info

Publication number
SG11202009526RA
SG11202009526RA SG11202009526RA SG11202009526RA SG11202009526RA SG 11202009526R A SG11202009526R A SG 11202009526RA SG 11202009526R A SG11202009526R A SG 11202009526RA SG 11202009526R A SG11202009526R A SG 11202009526RA SG 11202009526R A SG11202009526R A SG 11202009526RA
Authority
SG
Singapore
Prior art keywords
methods
ulcerative colitis
treating ulcerative
treating
colitis
Prior art date
Application number
SG11202009526RA
Other languages
English (en)
Inventor
James Benedict Canavan
Stuart William Friedrich
Kathryn Ann Krueger
Catherine Milch
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202009526RA publication Critical patent/SG11202009526RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202009526RA 2018-03-30 2019-03-28 Methods of treating ulcerative colitis SG11202009526RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
SG11202009526RA true SG11202009526RA (en) 2020-10-29

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009526RA SG11202009526RA (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Country Status (29)

Country Link
US (2) US12152072B2 (enrdf_load_stackoverflow)
EP (2) EP3773715B1 (enrdf_load_stackoverflow)
JP (4) JP7119114B2 (enrdf_load_stackoverflow)
KR (1) KR102552693B1 (enrdf_load_stackoverflow)
CN (1) CN111936165A (enrdf_load_stackoverflow)
AU (2) AU2019243283C1 (enrdf_load_stackoverflow)
BR (1) BR112020018099A2 (enrdf_load_stackoverflow)
CA (1) CA3095297A1 (enrdf_load_stackoverflow)
DK (1) DK3773715T3 (enrdf_load_stackoverflow)
EA (1) EA202091989A1 (enrdf_load_stackoverflow)
ES (1) ES2983809T3 (enrdf_load_stackoverflow)
FI (1) FI3773715T3 (enrdf_load_stackoverflow)
HR (1) HRP20240904T1 (enrdf_load_stackoverflow)
HU (1) HUE067445T2 (enrdf_load_stackoverflow)
IL (2) IL277514B2 (enrdf_load_stackoverflow)
LT (1) LT3773715T (enrdf_load_stackoverflow)
MA (1) MA52216B1 (enrdf_load_stackoverflow)
MD (1) MD3773715T2 (enrdf_load_stackoverflow)
MX (1) MX2020010269A (enrdf_load_stackoverflow)
MY (1) MY202368A (enrdf_load_stackoverflow)
PL (1) PL3773715T3 (enrdf_load_stackoverflow)
PT (1) PT3773715T (enrdf_load_stackoverflow)
RS (1) RS65661B1 (enrdf_load_stackoverflow)
SG (1) SG11202009526RA (enrdf_load_stackoverflow)
SI (1) SI3773715T1 (enrdf_load_stackoverflow)
TW (2) TWI837532B (enrdf_load_stackoverflow)
UA (1) UA128578C2 (enrdf_load_stackoverflow)
WO (1) WO2019191464A1 (enrdf_load_stackoverflow)
ZA (1) ZA202005388B (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
IL295545A (en) * 2020-02-14 2022-10-01 Janssen Biotech Inc Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
WO2021234634A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2022085739A1 (ja) * 2020-10-20 2022-04-28 協和化学工業株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
US20220259301A1 (en) * 2021-01-06 2022-08-18 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
MX2023013788A (es) * 2021-05-20 2024-02-13 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
WO2022251623A1 (en) * 2021-05-28 2022-12-01 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
KR20250111179A (ko) * 2022-11-22 2025-07-22 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
TW202500184A (zh) 2023-03-10 2025-01-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
WO2024255867A1 (zh) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501006A (ja) * 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗il−23抗体、組成物、方法および用途
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
MX2009009079A (es) 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
CA2741566A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.

Also Published As

Publication number Publication date
EA202091989A1 (ru) 2021-01-13
TWI744617B (zh) 2021-11-01
IL277514B1 (en) 2024-07-01
UA128578C2 (uk) 2024-08-21
RS65661B1 (sr) 2024-07-31
JP2021517156A (ja) 2021-07-15
US20250034243A1 (en) 2025-01-30
JP2023166388A (ja) 2023-11-21
US20210032325A1 (en) 2021-02-04
IL312807A (en) 2024-07-01
TW201946657A (zh) 2019-12-16
MD3773715T2 (ro) 2024-10-31
JP7331219B2 (ja) 2023-08-22
EP4327866A3 (en) 2024-03-20
BR112020018099A2 (pt) 2020-12-22
EP3773715B1 (en) 2024-05-08
ZA202005388B (en) 2025-05-28
HRP20240904T1 (hr) 2024-10-11
AU2019243283A1 (en) 2020-09-24
MX2020010269A (es) 2020-11-06
US12152072B2 (en) 2024-11-26
JP7119114B2 (ja) 2022-08-16
IL312807B2 (en) 2025-06-01
JP7571225B2 (ja) 2024-10-22
CN111936165A (zh) 2020-11-13
AU2019243283B2 (en) 2023-07-27
MA52216A (fr) 2021-02-17
NZ767902A (en) 2024-05-31
KR102552693B1 (ko) 2023-07-07
ES2983809T3 (es) 2024-10-24
HUE067445T2 (hu) 2024-10-28
LT3773715T (lt) 2024-06-25
PT3773715T (pt) 2024-05-27
PL3773715T3 (pl) 2024-08-19
EP3773715A1 (en) 2021-02-17
JP2022169562A (ja) 2022-11-09
TWI837532B (zh) 2024-04-01
DK3773715T3 (da) 2024-05-27
IL277514B2 (en) 2024-11-01
MA52216B1 (fr) 2024-07-31
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
CA3095297A1 (en) 2019-10-03
JP2025020134A (ja) 2025-02-12
AU2023248103A1 (en) 2023-11-09
IL312807B1 (en) 2025-02-01
SI3773715T1 (sl) 2024-06-28
MY202368A (en) 2024-04-24
KR20200128101A (ko) 2020-11-11
AU2019243283C1 (en) 2024-05-02
WO2019191464A1 (en) 2019-10-03
IL277514A (en) 2020-11-30
FI3773715T3 (fi) 2024-05-30

Similar Documents

Publication Publication Date Title
IL277514A (en) Methods for treating ulcerative colitis
ZA202006746B (en) Methods of treatment
ZA201903873B (en) Methods of treating cochlear synaptopathy
EP3319619A4 (en) Methods of treating colitis
IL267199A (en) A method for treating epilepsy
IL290069A (en) Methods for treating eye conditions
EP3684342C0 (en) TREATMENT METHOD
IL272092A (en) Methods for treating changes in behavior
IL256109A (en) Methods for the treatment or prevention of protopathy
GB201815588D0 (en) Method of treatment
GB201706406D0 (en) Method of treatment
IL287130A (en) Methods for treating itching
IL279917A (en) Treating ulcerative colitis with brazikumab
PL3356577T3 (pl) Obróbka w kąpieli wytrawiającej
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL272379B1 (en) Methods for treating cancer using SETDs inhibition
GB201602802D0 (en) Method of treatment
SG11202105877YA (en) Method of treatment
ZA201903931B (en) Method of treating meat
SG11201710199PA (en) Methods of treating multiple sclerosis
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
GB201720439D0 (en) Method of treatment
ZA201805402B (en) Treatment of contaminated water